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Down syndrome (DS) patients exhibit abnormalities of hippocampal-dependent explicit memory, a feature 
that is replicated in relevant mouse models of the disease. Adult hippocampal neurogenesis, which is impaired 
in DS and other neuropsychiatric diseases, plays a key role in hippocampal circuit plasticity and has been 
implicated in learning and memory. However, it remains unknown whether increasing adult neurogenesis 
improves hippocampal plasticity and behavioral performance in the multifactorial context of DS. We report 
that, in the Ts65Dn mouse model of DS, chronic administration of lithium, a clinically used mood stabilizer, 
promoted the proliferation of neuronal precursor cells through the pharmacological activation of the Wnt/ 
β-catenin pathway and restored adult neurogenesis in the hippocampal dentate gyrus (DG) to physiological 
levels. The restoration of adult neurogenesis completely rescued the synaptic plasticity of newborn neurons in 
the DG and led to the full recovery of behavioral performance in fear conditioning, object location, and novel 
object recognition tests. These findings indicate that reestablishing a functional population of hippocampal 
newborn neurons in adult DS mice rescues hippocampal plasticity and memory and implicate adult neurogen-
esis as a promising therapeutic target to alleviate cognitive deficits in DS patients.
Introduction
In mammals, new neurons are produced throughout life in 2 
neurogenic niches, i.e., the subventricular zone (SVZ) and the 
hippocampal dentate gyrus (DG). The DG plays a pivotal role in 
cognition. Experimental and computational studies indicate that 
newborn neurons in the DG are essential for hippocampal func-
tion due to the enhanced synaptic plasticity properties of these 
cells (i.e., increased intrinsic excitability and reduced sensitivity to 
GABAergic inhibition) compared with those of preexisting mature 
dentate granule cells (DGCs) (1–8). Given these peculiar electro-
physiological features, it has been proposed that maturing new-
born neurons distinctively contribute to information processing 
in the DG and participate in the expression of specific forms of 
hippocampal-dependent learning and memory in rodents, includ-
ing contextual learning (7, 9, 10), cognitive flexibility (11), and pat-
tern separation (12, 13).
The impairment of adult neurogenesis has been observed in a 
variety of models relevant to neuropsychiatric diseases, such as 
major depression, schizophrenia, and Alzheimer disease (14–18), 
and neurodevelopmental disorders, including fragile X and Down 
syndrome (DS) (19, 20). To date, there is no direct evidence sup-
porting a role for adult neurogenesis in specific diseases. However, 
recent data in epileptic patients undergoing en bloc hippocam-
pus resection indicate that low proliferation and differentiation 
capacities of adult hippocampal stem cells correlate with memory 
dysfunction (21). Yet adult neurogenesis is highly sensitive to envi-
ronmental stimuli, including environmental enrichment (22) and 
exogenous molecules (23). Thus, adult neurogenesis represents an 
attractive, though unexplored, opportunity to develop therapies 
for disease-associated cognitive impairment and might be par-
ticularly relevant for neurodevelopmental diseases with complex 
genetic etiologies, such as DS.
DS results from the trisomy of chromosome 21 in humans and 
is the leading cause of genetically defined intellectual disability. 
In the DS brain, suboptimal network architecture and altered 
synaptic communication through neurodevelopmental impair-
ment represent key determinants of intellectual disabilities in DS, 
which involve several cognitive domains, such as language, ver-
bal and spatial learning, and memory (reviewed in ref. 24). Both 
hippocampal and prefrontal-related functions appear defective in 
DS subjects (25–27), although these defects apparently manifest 
at different ages. Hippocampal dysfunction occurs in DS children 
and adolescents, with impairment of spatial associative memory 
as detected with the CANTAB Paired Associates Learning test and 
sparing of the prefrontal-mediated reference memory (25).
Over the past decades, several trisomic DS mouse models have 
been generated, recapitulating essential genetic and cognitive 
deficits of human DS (reviewed in ref. 24). The results of studies 
conducted in such models have suggested that cognitive dysfunc-
tion is not due to gross neuroanatomical abnormalities, but rather 
derives from both changes in synaptic connectivity (e.g., excitation/
inhibition imbalance) and altered developmental neurogenesis 
during embryogenesis and the early postnatal period (28–33). The 
widely used Ts65Dn mouse is a relevant model of DS, reproducing 
several phenotypic abnormalities of the human disease (34). Stud-
ies using this model have reported that neurogenesis is reduced in 
both the adult DG and SVZ, and the stimulation of neurogenesis 
using drugs, such as fluoxetine (35) or lithium (36), induces the 
proliferation of neural precursor cells (NPCs) and the expression 
of discrete molecular markers of newborn neurons in the DG and 
SVZ. However, the subsequent integration of adult-generated neu-
rons with the DS hippocampal circuit remains unexplored. More-
over, it is still unclear whether impairment of adult neurogenesis 
in DS is a primary event or a neuroadaptive response to complex 
pathological mechanisms. Nevertheless, independently of its ori-
gin, one fundamental question of potential therapeutic relevance 
is whether increasing adult neurogenesis improves hippocampal 
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plasticity and behavioral performance in the multifactorial con-
text of DS. In this study, we used 5- to 6-month-old adult Ts65Dn 
mice to investigate this critical point. To enhance neurogenesis, 
the mice were treated with lithium, a mood-stabilizing agent that 
specifically stimulates the proliferation of NPCs through the Wnt 
pathway (37, 38) without affecting gliogenesis (39).
The results showed that DG adult neurogenesis could be 
restored to physiological levels after 4 weeks of lithium adminis-
tration in the Ts65Dn trisomic mouse, resulting in the full recov-
ery of DG synaptic plasticity and hippocampal-dependent cogni-
tive functions, as determined using contextual fear conditioning 
(CFC), object location (OL), and novel object recognition (NOR) 
tasks. We also demonstrated that lithium treatment increased 
neurogenesis by stimulating NPC proliferation via the Wnt/ 
β-catenin pathway without affecting fate determination and new-
born neuron survival.
Results
Adult neurogenesis in the DG of Ts65Dn mice is restored to physiological levels 
using lithium. We initially examined the number of newborn neurons 
in the Ts65Dn DG and established a protocol for promoting adult 
neurogenesis through the administration of lithium, a widely used 
mood stabilizer that stimulates the proliferation of NPCs via Wnt 
signaling (37, 38). To visualize newborn neurons, we evaluated the 
early neuronal marker doublecortin (DCX), which is expressed from 
the late precursor stage until 3 to 4 weeks after newly generated neu-
rons become postmitotic (Figure 1A and ref. 40). We observed that 
the number of maturing newborn neurons expressing DCX was 
reduced by 60% in the DG of untreated Ts65Dn mice (Figure 1, B 
and C). Four weeks of treatment with lithium (Li2CO3, 2.4 g/kg of 
chow) fully restored the number of DCX+ neurons in the DG of tri-
somic mice to levels comparable with those of untreated WT litter-
mates (Figure 1, B and C). The number of DCX+ newborn neurons 
was also augmented in the lithium-treated WT mice. However, the 
lithium-induced increase was much higher in trisomic mice (174%) 
than in the WT littermates (50%). Similar results were obtained 
when neurogenesis was evaluated using the neuronal marker cal-
retinin (CR), which is transiently expressed in adult-born neurons 
until 1 to 2 weeks after their birth (Figure 1A and ref. 40). The num-
ber of CR+ neurons was reduced by 45% in the DG of untreated 
Ts65Dn mice and increased in both WT mice (53%) and trisomic 
littermates (173%) after lithium treatment (Figure 1, D and E).
Enhancing adult neurogenesis rescues DG synaptic plasticity in Ts65Dn 
mice. Next, we examined whether the reduced neurogenesis in 
Ts65Dn mice was associated with impaired DG synaptic plasticity 
(29) and whether lithium-rescued newborn neurons were physio-
logically functional. It has been demonstrated that, at 3 to 4 weeks 
after becoming postmitotic, maturing newborn neurons exhibit 
unique electrophysiological features, including increased excitabil-
ity, enhanced synaptic plasticity, insensitivity to GABA inhibition, 
and a lower threshold for the induction of long-term potentiation 
(LTP) than mature DGCs (2–4, 6, 8). Neurogenesis-dependent 
LTP relies on the activation of glutamate receptors containing the 
NR2B subunit and can be induced in the DG in the presence of 
intact GABAergic inhibition. Conversely, the LTP of preexisting 
mature DGCs can only be induced when local GABAergic inhibi-
tion is blocked (1, 5, 7, 11, 12).
We observed that while basal synaptic transmission and short-
term plasticity were normal (Supplemental Figure 1, A and B; sup-
plemental material available online with this article; doi:10.1172/
JCI64650DS1), high-frequency stimulation of the medial per-
forant path (MPP) failed to elicit LTP in artificial cerebrospinal 
fluid (ACSF-LTP) in Ts65Dn hippocampal slices in the absence of 
GABAA receptor blockers (Figure 2, B and F). Remarkably, 4 weeks 
of lithium treatment reestablished ACSF-LTP in Ts65Dn mice to 
levels indistinguishable from those in untreated WT littermates 
(Figure 2, C and F). The bath application of the NR2B antago-
nist Ro25-6981 blocked potentiation in slices from lithium-fed 
Ts65Dn mice and untreated or lithium-treated WT littermates, 
thus confirming the specific induction of newborn neuron–depen-
dent ACSF-LTP (Figure 2, D and F, and Supplemental Figure 1, 
C–E). Conversely, high-frequency stimulation in the presence of 
the GABAA receptor blocker picrotoxin (PTX) elicited comparable 
potentiation (PTX-LTP) in hippocampal slices from both treated 
and untreated WT and Ts65Dn mice (Supplemental Figure 1, 
F–H), indicating that synaptic plasticity of mature DGCs is unaf-
fected in Ts65Dn mice and is not modulated by lithium.
Functional newborn neurons are necessary for LTP recovery. We 
evaluated whether the effects of lithium on synaptic poten-
tiation were dependent on functional neurogenesis. Thus, we 
examined LTP after a 1-week administration of lithium, which 
is sufficient to develop therapeutic concentrations of lithium 
in the mouse (Supplemental Figure 2) and rat brain (41), but 
inadequate for newly generated neurons to integrate into the 
hippocampal circuit (Figure 1A and refs. 2, 4). Indeed, the short-
term lithium treatment failed to restore potentiation in Ts65Dn 
mice and did not change LTP in WT littermates (Figure 2, E and 
F), highlighting the requirement of functional neurogenesis for 
synaptic potentiation.
We further investigated whether newborn neurons were necessary 
for the lithium-mediated rescue of LTP in the DG of Ts65Dn mice 
through the administration of a low dose of the cytostatic drug 
temozolomide (TMZ), which has been shown to block adult neu-
rogenesis, neurogenesis-dependent ACSF-LTP, and spatial memory 
without detectable side effects (11, 42). Initial experiments in WT 
mice confirmed that TMZ treatment inhibited neurogenesis in a 
concentration-dependent manner, reducing the number of DCX+ 
neurons to approximately 18% and 48% at 12.5 and 25 mg/kg, 
respectively (Supplemental Figure 3). Notably, only a high dose of 
TMZ inhibited the induction of neurogenesis-dependent ACSF-LTP 
(Supplemental Figure 3, C and D), while the low dose was ineffec-
tive on synaptic plasticity. Consistent with previous results (11), 
a 25 mg/kg TMZ treatment did not alter the LTP of mature DG 
neurons (PTX-LTP) or affect potentiation at Shaffer collateral-CA1 
synapses (CA3-CA1 LTP) (Supplemental Figure 3, E–H). This find-
ing indicates that, at this dose, TMZ specifically impairs neurogen-
esis-dependent LTP without affecting the functional properties of 
other hippocampal neuronal populations in WT mice, consistent 
with the preserved density of NeuN+ neurons in the CA1 and CA3 
regions of the hippocampus (Supplemental Figure 4). Similarly, in 
Ts65Dn mice, TMZ further reduced the number of DCX+ newborn 
neurons without changing the density of NeuN+ neurons, indicat-
ing a selective effect on adult neurogenesis.
When coadministered with lithium, TMZ reduced the number 
of DCX+ newborn neurons in both Ts65Dn mice and WT litter-
mates, completely blocking the effects of lithium. Indeed, the 
number of newborn neurons was reduced by 59% in Ts65Dn mice 
and by 64% in WT littermates treated with both TMZ and lithium 
compared with mice of the same genotype treated with lithium 
alone (Figure 3A). Consistently, ACSF-LTP was abolished in both 
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WT and Ts65Dn mice treated with lithium and TMZ (Figure 3, 
B–D). Importantly, TMZ treatment did not affect DG basal synap-
tic transmission and short-term plasticity (Supplemental Figure 5, 
A and B) or the LTP of mature dentate neurons (PTX-LTP) in both 
Ts65Dn and WT mice (Supplemental Figure 5, C–E), confirming 
the selective impairment of neurogenesis-dependent ACSF-LTP.
Overall, these data indicate that the effects of lithium depend on 
functional neurogenesis and that newborn neurons are required to 
fully rescue LTP in the DG of Ts65Dn mice.
Restoring adult neurogenesis specif ically rescues hippocampal-
dependent long-term explicit memory in Ts65Dn mice. Ts65Dn mice 
exhibit learning and memory deficits in several tasks, including 
Figure 1
Lithium restored the number of newborn neurons in DG of adult Ts65Dn mice. (A) Expression of molecular markers during adult DG neurogen-
esis. During the mitotic phase, 2 types of progenitors proliferate in the SGZ of the DG: RGL progenitors (type I cells, expressing Nestin, GFAP, 
and Sox2) and amplifying progenitors (type II cells, expressing Sox2 only). Before becoming postmitotic, the progenitors undergo a short inter-
mediate stage (neuroblasts), commit to the neuronal fate, and begin expressing DCX. In the postmitotic phase, DCX-positive newborn neurons 
derived from neuroblasts undergo a morphological and physiological maturing process with the sequential expression of CR and NeuN upon 
final maturation. (B–E) Five- to six-month-old Ts65Dn and WT mice were treated with lithium or saline for 4 weeks, and the number of newborn 
neurons was evaluated through immunohistochemistry for DCX or CR (red) and counterstained with Hoechst-33342 (blue). (B) Immunoreactivity 
and (C) number of DCX+ newborn neurons in saline- or lithium-treated Ts65Dn and WT mice. 2-way ANOVA: genotype (F1,20 = 19.285, P < 0.001), 
treatment (F1,20 = 25.570, P < 0.001), genotype × treatment (F1,20 = 0.584, P = 0.454). (D) Immunoreactivity and (E) number of CR+ newborn 
neurons in DG of saline- or lithium-treated Ts65Dn and WT mice. 2-way ANOVA: genotype (F1,20 = 2.413, P = 0.136), treatment (F1,20 = 26.602, 
P < 0.001), genotype × treatment (F1,20 = 2.247, P = 0.149). Numbers in parentheses indicate the number of animals in each group. *P < 0.05; 
**P < 0.01, Tukey’s post hoc test. Scale bars: 100 μm (B); 25 μm (D).
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spatial memory (34), context learning (43), object discrimina-
tion (28), and working memory (28). Therefore, we determined 
whether rescuing adult neurogenesis and DG synaptic plastic-
ity resulted in the recovery of hippocampus-dependent long-
term explicit memory in Ts65Dn mice. We subjected the mice 
to a battery of 3 behavioral tasks (i.e., CFC, OL, and NOR) that 
depend on intact adult neurogenesis (7, 10, 44–48). We observed 
that untreated Ts65Dn mice displayed a strong impairment in 
all 3 behavioral tests (Figure 4). This behavioral phenotype was 
independent of motor performance, as motor activity was not 
significantly different across genotypes and treatments (dis-
tance traveled, WT saline: 34.4 ± 2.2 m, n = 13; Ts65Dn saline: 
44.1 ± 3.8 m, n = 12; WT lithium: 31.4 ± 2.9 m, n = 15; Ts65Dn lith-
ium: 39.9 ± 5.7 m, n = 11. 2-way ANOVA: genotype [F1,47 = 6.133, 
P = 0.017], treatment [F1,47 = 0.933, P = 0.339], genotype × treat-
ment [F1,47 = 0.0249, P = 0.875]).
Consistent with previous reports (43), untreated Ts65Dn mice 
showed a reduced freezing response in the CFC test, indicating 
impaired associative learning. Remarkably, a 4-week lithium admin-
istration fully restored contextual learning in Ts65Dn mice, which 
performed indistinguishably from WT littermates (Figure 4A). 
To exclude the potential confounding effects on the freezing 
response (i.e., nonassociative freezing), the mice were exposed to 
a new context at 2 hours after the test. All groups of mice showed 
negligible freezing in the new context, irrespective of genotype and 
treatment (Figure 4A).
We also evaluated the ability of mice to discriminate the new 
location of an object in relation to spatial information using the 
OL test. Untreated Ts65Dn mice were incapable of discriminat-
ing the new location after a 24-hour retention interval. However, 
after lithium administration for 4 weeks, the Ts65Dn mice com-
pletely recovered spatial memory in the OL test (Figure 4B). The 
total object exploration time was not significantly different across 
genotype and treatment groups during the acquisition and trial 
phases, ruling out any interference due to animal motivation or 
amount of exploration (Supplemental Figure 6, A–C).
We also used the NOR test to evaluate the ability of mice to dis-
criminate novelty in a complex setting of 3 different objects (49). 
Consistent with the results of previous studies (28), Ts65Dn mice 
were unable to discriminate the novel object over a 24-hour reten-
tion period. Notably, Ts65Dn mice treated with lithium for 4 weeks 
showed discrimination ability equivalent to WT littermates, indi-
Figure 2
Restoration of adult neurogenesis rescued newborn neuron–dependent synaptic plasticity in the DG of Ts65Dn mice. fEPSPs in the DG medial 
molecular layer elicited through the stimulation of the MPP in ACSF were recorded in hippocampal slices obtained from Ts65Dn and WT mice 
fed with normal or lithium-containing diets for either 1 or 4 weeks. (A) Position of the stimulating and recording electrodes. (B) ACSF-LTP was 
induced in hippocampal slices from saline-treated WT (P < 0.01 vs. baseline) but not Ts65Dn mice (P = 0.190). (C) ACSF-LTP was restored in 
hippocampal slices of Ts65Dn mice (P < 0.01) and increased in slices from WT littermates (P < 0.01) after 4 weeks of lithium treatment. (D) ACSF-
LTP was inhibited through the specific NR2B antagonist Ro25-6981 (1.5 μM) in hippocampal slices from WT (P = 0.469) and Ts65Dn (P = 0.091) 
mice treated with lithium for 4 weeks. (E) ACSF-LTP was induced in hippocampal slices of WT (P < 0.001) but not Ts65Dn (P = 0.802) mice treated 
with lithium for only 1 week. The insets in B–E show representative fEPSP traces recorded 5 minutes before (black) and 45 minutes after (gray) LTP 
induction. (F) Quantification of ACSF-LTP elicited in the DG of WT and Ts65Dn mice. Numbers in parentheses indicate the number of slices record-
ed for each experimental group. 2-way ANOVA: genotype (F1,43 = 16.721, P < 0.001), treatment (F3,43 = 25.431, P < 0.001), genotype × treatment 
(F3,43 = 4.996, P = 0.005). *P < 0.05; **P < 0.01, Tukey’s post hoc test.
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cating a full recovery of memory functions (Supplemental Figure 7, 
A and B). The total exploration time during sessions and prefer-
ence toward different objects in Ts65Dn mice following 4-week 
lithium treatment was similar to untreated Ts65Dn and WT mice 
(Supplemental Figure 7, C–E).
Next, we examined whether the effects of lithium on hippo-
campal-dependent cognitive tasks were dependent on func-
tional neurogenesis. Consistent with the notion that newborn 
neurons younger than 1 week are not yet functionally integrat-
ed and the lack of LTP recovery in Ts65Dn mice after 1 week of 
lithium administration (Figure 2, E and F), we did not detect any 
improvement of memory deficits in the CFC (percentage freezing 
time, WT: 50.3 ± 10.8, n = 4; Ts65Dn: 24.50 ± 5.0, n = 6; P < 0.05, 
Student’s t test), OL (discrimination index, WT: 25.2 ± 5.2, n = 11; 
Ts65Dn: 1.1, ± 7.8, n = 11; P < 0.05, Student t test), and NOR tests 
(Supplemental Figure 7B) after short-term lithium treatment.
We further investigated whether newborn neurons were required 
for the lithium-mediated rescue of hippocampus-dependent cog-
nitive impairment through the administration of TMZ. Consis-
tent with the observations in DCX+ newborn neurons and neu-
rogenesis-dependent ACSF-LTP (Figure 3), the lithium-induced 
cognitive recovery was abolished in Ts65Dn mice in which neu-
rogenesis was concomitantly inhibited through TMZ administra-
tion. WT and Ts65Dn mice treated with both lithium and TMZ 
showed impaired contextual learning in the CFC test (Figure 4A) 
and were incapable of discriminating the new OL compared with 
mice treated with lithium alone (Figure 4B), indicating that new-
born neurons are required to rescue hippocampal-mediated mem-
ory in Ts65Dn mice.
To assess the specificity of lithium for neurogenesis-dependent 
cognitive tasks, we examined working memory using the spon-
taneous alternation task. Working memory depends on intact 
hippocampal functions, engages several other brain areas (50), and 
appears to be independent of adult neurogenesis (51). Consistent 
with the results of previous studies (28), Ts65Dn mice could not alter-
nate in the T-maze and performed close to chance level (Figure 4C). 
Notably, lithium treatment did not rescue Ts65Dn working mem-
ory performance in the T-maze. Total arm entries were similar 
across all genotype and treatment groups (Figure 4C). These results 
indicate that lithium specifically rescued Ts65Dn cognitive perfor-
mance in cognitive memory domains sensitive to functional adult 
neurogenesis, without affecting other brain functions.
Figure 3
Adult neurogenesis was required for lithium-induced rescue of LTP in Ts65Dn mice. (A) Number of DCX+ newborn neurons in the DG of Ts65Dn 
and WT mice in which neurogenesis was inhibited using TMZ. 2-way ANOVA: genotype (F1,40 = 40.057, P < 0.001), treatment (F3,40 = 47.089, 
P < 0.001), genotype × treatment (F3,40 = 3.375, P = 0.028). (B) The inhibition of neurogenesis using TMZ prevented ACSF-LTP induction in slices 
obtained from lithium-treated WT mice (P = 0.690 vs. baseline). The LTP was normally induced in WT mice treated with either saline/vehicle 
(P < 0.001) or lithium/vehicle (P < 0.001). (C) The inhibition of neurogenesis using TMZ prevented ACSF-LTP induction in slices obtained from lith-
ium-treated Ts65Dn (P = 0.105) mice. LTP was absent in Ts65Dn mice receiving saline/vehicle (P = 0.101) and was restored in the lithium-treated 
group (P < 0.001). The insets in panels B and C show representative fEPSP traces recorded 5 minutes before (black) and 45 minutes after (gray) 
LTP induction. (D) Quantification of the extent of ACSF-LTP elicited in the DG of WT and Ts65Dn mice. The numbers in parentheses indicate 
the number of brain slices recorded for each experimental group. 2-way ANOVA: genotype (F1,36 = 16.406, P < 0.001), treatment (F2,36 = 70.531, 
P < 0.001), genotype × treatment (F2,36 = 11.404, P < 0.001). *P < 0.05; **P < 0.01 Tukey’s post hoc test.
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Lithium restores neurogenesis in Ts65Dn mice through NPC prolifera-
tion. We determined whether lithium promoted adult neurogen-
esis through NPC proliferation or the survival of newly gener-
ated cells in Ts65Dn mice. The number of proliferating cells (as 
assessed using Ki67 staining) was decreased by 56% in Ts65Dn 
mice (Figure 5, A and B). Amplifying precursors (type II cells) 
(40, 52) were also reduced by 41% in Ts65Dn mice, while the num-
ber of radial glia-like (RGL) progenitors (type I cells) was not sig-
nificantly different from that in WT littermates (Figure 5, C–E). 
Lithium treatment for 4 weeks increased the number of amplify-
ing progenitors and Ki67+ cells, thereby restoring the prolifera-
tion of NPCs in Ts65Dn mice (Figure 5, B and E).
BrdU birth dating (Figure 6A) confirmed the impairment of NPC 
proliferation in the DG of Ts65Dn mice, showing that BrdU+ cells 
were reduced by 48% compared with those in WT mice (Figure 6, 
B and C). This impairment was paralleled by a 57% reduction in the 
number of BrdU+ newly generated neurons expressing the mature 
neuronal marker NeuN in the DG of trisomic mice (Figure 6, 
D and E). Notably, lithium promoted the proliferation of NPCs 
in the DG of Ts65Dn mice (Figure 6C) and restored the number 
of newly generated BrdU+NeuN+ neurons at 4 weeks after BrdU 
administration (Figure 6E).
In addition, we examined the survival of newly generated cells 
and their commitment toward the neuronal lineage in lithium-
treated and untreated mice. The total numbers of surviving 
BrdU+ cells and their progeny at 4 weeks after BrdU adminis-
tration were reduced by 54% in untreated Ts65Dn mice. How-
ever, the survival rate of BrdU+ cells in all Ts65Dn treatment 
groups was similar to that in the untreated WT littermates (Fig-
ure 6G). This indicates that the reduction of newborn neurons 
in Ts65Dn mice was not a consequence of cell death and that 
lithium did not affect the survival of newly generated cells. Con-
sistently, the number of apoptotic cells was not significantly 
different between untreated or lithium-fed Ts65Dn mice and 
WT untreated littermates (Supplemental Figure 8). In WT mice, 
despite enhanced NPC proliferation (59% over basal), lithium 
treatment did not enhance the total number of surviving BrdU+ 
cells or newly generated neurons (BrdU+NeuN+), resulting in a 
significant reduction in the survival rates of these cells. This 
suggests the existence of physiological regulatory mechanisms 
that balance the excess production of newly generated cells in 
WT mice as previously proposed (53). This view is supported 
by the observation that the number of apoptotic cells was sig-
nificantly increased in the DG of WT mice after lithium treat-
ment (Supplemental Figure 8), and the number of BrdU+NeuN+ 
newborn neurons was similar in both lithium-treated WT and 
Ts65Dn mice (Figure 6E).
Finally, the phenotypic analysis of newly generated BrdU+ cells 
revealed that the percentage of BrdU+GFAP+ cells was similar in 
treated and untreated WT and Ts65Dn mice. Conversely, a slightly 
significant reduction (5%) of the percentage of BrdU+NeuN+ over 
the total number of BrdU+ cells was observed in untreated Ts65Dn 
mice. Lithium treatment restored the BrdU+NeuN+ cell number, 
suggesting that the altered acquisition of the neuronal phenotype 
might also partially contribute to the impaired generation of new-
born neurons in trisomic mice (Figure 6H).
The Wnt/β-catenin pathway is required to promote NPC proliferation. 
The Wnt/β-catenin signaling pathway plays a key role in regu-
lating DG adult neurogenesis (39) and is involved in regulating 
hippocampal NPC proliferation upon lithium stimulation in 
vitro (38). To confirm the activation of this pathway upon lithium 
administration (54), we evaluated the amount of active β-catenin 
Figure 4
Reinstating adult neurogenesis rescued behavioral performance of Ts65Dn mice in CFC and OL tasks. (A) Ts65Dn contextual memory was res-
cued through a 4-week treatment with lithium. No effects were detected when mice were treated with lithium for 1 week. 2-way ANOVA: genotype 
(F1,69 = 10.107, P = 0.002), treatment (F2,69 = 2.383, P = 0.100), genotype × treatment (F2,69 = 2.589, P = 0.082). No effect was observed when mice 
were exposed to a new context. 2-way ANOVA: genotype (F1,69 = 1.738, P = 0.192), treatment (F2,69 = 0.551, P = 0.579), genotype × treatment 
(F2,69 = 0.069, P = 0.933). (B) Four weeks of lithium treatment fully rescued spatial memory deficits in Ts65Dn mice in the OL test. The inhibi-
tion of adult neurogenesis through TMZ prevented lithium effects. 2-way ANOVA: genotype (F1,162 = 0.123, P = 0.726), treatment (F2,162 = 7.009, 
P = 0.001), genotype × treatment (F2,162 = 2.926, P = 0.056). (C) Alternation in the T-maze test was reduced in Ts65Dn mice (dashed line indicates 
chance alternation) and was not affected by lithium. 2-way ANOVA: genotype (F1,36 = 13.816, P < 0.001), treatment (F1,36 = 0.118, P = 0.734), 
genotype × treatment (F1,36 = 0.127, P = 0.724). The total number of arm entries during the test was not different across genotype and treatment. 
2-way ANOVA: genotype (F1,36 = 0.345, P = 0.560), treatment (F1,36 = 0.701, P = 0.408), genotype × treatment (F1,36 = 0.051, P = 0.823). In all 
panels, the numbers in parentheses indicate numbers of animals per group. *P < 0.05; **P < 0.01 Tukey’s post hoc test.
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(i.e., dephosphorylated at Ser37 and Thr41) (55, 56) in hippocampal 
lysates from WT and Ts65Dn mice using quantitative multiplex 
fluorescent Western blotting (57). Lithium treatment effectively 
increased the ratio of active β-catenin to total β-catenin in both WT 
and Ts65Dn hippocampi. Notably, the extent of lithium-induced 
β-catenin activation was significantly greater in Ts65Dn mice (48%) 
than in their WT littermates (18%) (Figure 7A).
To investigate whether the lithium-mediated stimulation 
of this pathway induces NPC proliferation in Ts65Dn mice in 
a cell-autonomous manner, we established in vitro cultures of 
adult dentate NPCs (ADNPCs) (58) from WT and Ts65Dn mice. 
We first examined whether the proliferation of ADNPCs from 
Ts65Dn mice was altered in vitro. Proliferating ADNPCs from 
WT and Ts65Dn mice expressed comparable levels of the pre-
cursor markers Nestin and Sox2 
(Figure 7B). BrdU incorporation 
experiments demonstrated that the 
proliferation of Ts65Dn ADNPCs 
was significantly reduced com-
pared with WT cultures (Figure 7, 
C and D). Consistent with in vivo 
findings, lithium treatment almost 
doubled ADNPC proliferation in 
both WT and Ts65Dn cultures. 
Notably, the percentage of BrdU+ 
cells in Ts65Dn cultures was 
restored to levels indistinguishable 
from untreated WT ADNPCs.
The activation of the Wnt path-
way leads to the stabilization and 
nuclear translocation of β-catenin, 
which, in turn, activates the expres-
sion of Wnt target genes through 
interactions with members of the 
T cell factor/lymphoid enhancer 
factor (TCF/LEF) family of tran-
scription factors (59). We there-
fore verified whether the canoni-
cal Wnt/β-catenin pathway was 
activated through lithium treat-
ment in ADNPCs using the TOP-
Flash and FOPFlash luciferase 
reporter assay (60). Treatment 
with recombinant Wnt3a sig-
nificantly increased β-catenin/
TCF-dependent transcription in 
both WT (fold induction ± SEM: 
11.67 ± 2.02; P < 0.01 versus basal, 
unpaired t  test) and Ts65Dn 
ADNPCs (fold induction ± SEM: 
9.81 ± 1.97; P < 0.01 versus basal, 
unpaired t test) and achieved simi-
lar levels of activity in both WT 
and Ts65Dn cells (NS, unpaired t 
test), indicating that this pathway 
is functional upon ligand stimula-
tion. Notably, lithium significantly 
enhanced β-catenin/TCF-depen-
dent transcription in ADNPCs from 
WT and Ts65Dn mice under basal 
conditions and in the presence of Wnt3a (Figure 7E), confirming 
that lithium induces the activation of Wnt/β-catenin signaling.
Moreover, we assessed whether the Wnt/β-catenin/TCF pathway 
was required for the proliferative effects of lithium. To inhibit the 
β-catenin function, we transfected ADNPCs from WT and Ts65Dn 
mice with a dominant negative form of TCF4 (dnTCF) (61) togeth-
er with the fluorescent reporter protein mCherry (dnTCF-mCher-
ry). Lithium-induced proliferation was completely abolished in 
ADNPCs transfected with dnTCF-mCherry, while the expression 
of mCherry alone neither affected basal nor lithium-induced prolif-
eration in both WT and Ts65Dn ADNPCs (Figure 7F). The baseline 
activity of Wnt signaling in cultured ADNPCs was modest, and the 
expression of dnTCF did not substantially affect the basal prolifer-
ation rate of ADNPCs (Figure 7F), consistent with previous reports 
Figure 5
Lithium restored the number of proliferating cells and increased the number of amplifying progenitors in 
Ts65Dn mice. (A) Ki67 immunoreactivity (green) and nuclei counterstaining with Hoechst-33342 (blue). 
Scale bar:100 μm. (B) Number of Ki67-stained cells. Proliferating cells were reduced in saline-treated 
Ts65Dn mice. Lithium treatment for 4 weeks significantly increased the number of Ki67+ cells in WT 
mice (black bars) and restored their number to physiological levels in Ts65Dn mice (white bars). 2-way 
ANOVA: genotype (F1,20 = 8.383, P = 0.009), treatment (F1,20 = 21.493, P < 0.001), genotype × treatment 
(F1,20 = 1.029, P = 0.322). (C) RGL progenitors (arrowheads) and amplifying progenitors (arrows) immu-
noreactive for GFAP (red) and Sox2 (green) and counterstained with Hoechst-33342 (blue). Scale bar: 
25 μm. (D and E) Number of RGL progenitors and amplifying progenitors was evaluated by counting 
GFAP- and Sox2-positive cells with or without radial morphology (see Methods). (D) Number of RGL 
progenitors in lithium- or saline-treated mice showed no differences across groups. 2-way ANOVA: geno-
type (F1,20 = 0.261, P = 0.615), treatment (F1,20 = 0.364, P = 0.553), genotype × treatment (F1,20 = 0.746, 
P = 0.398). (E) Number of amplifying progenitors was reduced in Ts65Dn mice and significantly increased 
by lithium treatment. 2-way ANOVA: genotype (F1,20 = 17.155, P < 0.001), treatment (F1,20 = 2.772, 
P = 0.112), genotype × treatment (F1,20 = 4.217, P = 0.053). *P < 0.05; **P < 0.01, Tukey’s post hoc test. 
Numbers in parentheses indicate the number of animals analyzed in each group.
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showing that the knockdown of β-catenin did not affect the basal 
proliferation of adult hippocampal progenitors in culture (38).
Overall, these data indicate that lithium activates the Wnt/ 
β-catenin pathway in the hippocampus in vivo and that this path-
way is required for the effects of lithium on ADNPC proliferation.
Discussion
Our findings demonstrate that promoting adult neurogenesis 
mediates the functional recovery of synaptic plasticity in the DG 
and rescues behavioral performance in hippocampal-mediated 
tasks in a relevant mouse model of DS. Lithium, a well-established 
Figure 6
Lithium restored neurogenesis by promoting NPC proliferation in DG of Ts65Dn mice. (A) Experimental design. (B) BrdU immunoreactivity 
(green) and nuclei counterstaining with Hoechst-33342 (blue). Scale bar: 100 μm. (C) Number of BrdU+ cells in mice sacrificed at 24 hours 
after BrdU administration. 2-way ANOVA: genotype (F1,20 = 34.753, P < 0.001), treatment (F1,20 = 65.834, P < 0.001), genotype × treatment 
(F1,20 = 0.009, P = 0.921). (D) BrdU (green), NeuN (red), and GFAP (cyan) immunoreactivity of brain slices from mice sacrificed at 4 weeks after 
BrdU administration. Scale bar: 25 μm. (E and F) Number of newly generated neurons (BrdU+NeuN+) (E; 2-way ANOVA: genotype [F1,20 = 5.311, 
P = 0.032], treatment [F1,20 = 11.804, P = 0.003], genotype × treatment [F1,20 = 8.871, P = 0.007]) and total BrdU+ cells (F; 2-way ANOVA: genotype 
[F1,20 = 7.430, P = 0.013], treatment [F1,20 = 19.013, P < 0.001], genotype × treatment [F1,20 = 12.480, P = 0.002]) in DG of Ts65Dn and WT mice 
4 weeks after BrdU administration. (G) Survival rate of BrdU+ cells and their progeny. 2-way ANOVA: genotype (F1,20 = 1.293, P = 0.2690), treat-
ment (F1,20 = 2.335, P = 0.1422), genotype × treatment (F1,20 = 5.410, P = 0.0307). (H) Percentage distribution of BrdU+NeuN+, BrdU+GFAP+, and 
BrdU+ only–labeled cells. 2-way ANOVA for BrdU+NeuN+: genotype (F1,20 = 0.381, P = 0.544), treatment (F1,20 = 0.974, P = 0.336), genotype × 
treatment (F1,20 = 5.758, P = 0.0264). 2-way ANOVA for BrdU+GFAP+: genotype (F1,20 = 1.958, P = 0.177), treatment (F1,20 = 0.162, P = 0.691), 
genotype × treatment (F1,20 = 0.643, P = 0.432). 2-way ANOVA for BrdU+ only: genotype (F1,20 = 0.105, P = 0.749), treatment (F1,20 = 0.388, 
P = 0.540), genotype × treatment (F1,20 = 6.884, P = 0.016). *P < 0.05; **P < 0.01, Tukey’s (C and E–G) or Bonferroni’s (H) post hoc tests. Numbers 
in parentheses indicate the number of animals analyzed in each group.
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Figure 7
Lithium rescued proliferation of Ts65Dn NPCs through stimulation of β-catenin pathway. (A) Multiplex fluorescence Western blot analysis of active 
form of β-catenin in hippocampal lysates from WT and Ts65Dn mice. The ratio of active β-catenin (green) to total β-catenin (red). 2-way ANOVA: 
genotype (F1,12 = 8.576, P = 0.013), treatment (F1,12 = 41.168, P < 0.001), genotype × treatment (F1,12 = 8.439, P = 0.013). (B) ADNPC immuno-
reactivity for the progenitor markers Sox2 (green) and Nestin (red). (C) BrdU immunoreactivity (green) in ADNPCs counterstained with DAPI 
(red). Scale bars: 20 μm. (D) Percentage of BrdU+ cells in Ts65Dn ADNPCs treated with lithium (2 mM LiCl ) or vehicle. 2-way ANOVA: genotype 
(F1,12 = 17.431, P < 0.001), treatment (F1,12 = 19.044, P < 0.001), genotype × treatment (F1,12 = 0.317, P = 0.584), (n = 4). (E) Wnt/β-catenin path-
way activation as detected using the TOPFlash and FOPFlash plasmid luciferase reporter assay. Treatment with lithium increased luciferase 
activity in ADNPCs under basal conditions (1-way ANOVA [F3,20 = 7.448, P = 0.002]) and upon stimulation with 10 ng/ml of Wnt3a (1-way ANOVA 
[F3,20 = 14.643, P < 0.001]). (F) Proliferation analysis in ADNPCs transfected with dnTCF-mCherry (EdTC) or control mCherry plasmids. Prolifera-
tion was expressed as the ratio of BrdU+mCherry+ double-labeled cells to total mCherry+ cells (n = 4). 2-way ANOVA: genotype (F1,24 = 357.0, 
P < 0.001), treatment (F3,24 = 194.0, P < 0.001), genotype × treatment (F3,24 = 8.446, P < 0.001). *P < 0.05; **P < 0.01, Tukey’s post hoc test.
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mood stabilizer, stimulates NPC proliferation and increases the 
number of maturing DG newborn neurons in trisomic mice. These 
neurons are functionally active, as demonstrated by the complete 
recovery of newborn neuron–dependent LTP in the DG of lithi-
um-treated Ts65Dn mice, and are required to restore learning and 
memory performance in trisomic mice. The neurogenesis-pro-
moting effects of lithium are associated with the activation of the 
Wnt/β-catenin pathway in vivo, and functional signaling through 
this pathway is required for the lithium-induced proliferation of 
both trisomic and WT ADNPCs in vitro.
Consistent with previous results (28, 29), we observed that LTP 
elicited in the absence of GABAA receptor blockers (ACSF-LTP) is 
deficient in Ts65Dn mice. It has been demonstrated that this form 
of LTP is dependent on functional DG newborn neurons, which 
express glutamate receptors containing the NR2B subunit (1, 2, 7). 
The lack of ACSF-LTP in trisomic mice is indeed consistent with 
the reduced number of newborn neurons in the DG (Figure 1). 
Notably, chronic lithium administration restores the prolifera-
tion of NPCs and the generation of newborn neurons, leading 
to the full recovery of Ro25-6981–sensitive LTP in trisomic mice. 
Moreover, LTP was not induced when trisomic and WT mice were 
administered lithium in combination with the cytostatic drug 
TMZ, indicating that neurogenesis is required for LTP induction 
when the GABAergic system is not inhibited. Thus, short-term 
treatment (e.g., 1 week) with lithium did not restore hippocampal 
synaptic plasticity in Ts65Dn mice, thereby ruling out the involve-
ment of other acute effects of lithium and further supporting the 
notion that functional neurogenesis is specifically involved in 
reverting the hippocampal-dependent disease phenotype. Indeed, 
newborn neurons 1-week old or younger do not show any spon-
taneous or evoked synaptic currents and are not integrated in the 
hippocampal circuits (4, 62). Indeed, the enhanced synaptic plas-
ticity properties of these cells are expressed at 3–4 weeks after their 
birth and last until 6 weeks (2, 3).
The recovery of neurogenesis and newborn neuron–dependent 
LTP in Ts65Dn mice specifically rescues behavioral performance 
in 3 distinct hippocampal-dependent tasks (i.e., CFC, OL, and 
NOR) but does not rescue working memory (i.e., T-maze alterna-
tion). This finding is consistent with previous studies showing that 
contextual learning (7, 9, 10), spatial memory, and object discrimi-
nation (44, 45, 47, 63) rely on hippocampal adult neurogenesis, 
while working memory engages several brain areas, including the 
prefrontal cortex, basal forebrain, hippocampus, and striatum (50), 
and is independent of adult neurogenesis (51). Chronic treatment 
with lithium also increased the number of newborn neurons and 
neurogenesis-dependent LTP in WT mice. However, these effects 
do not translate into behavioral benefits. This finding is consis-
tent with recent data demonstrating that increasing the number 
of DCX+ newborn neurons through the genetic inhibition of apop-
tosis potentiates neurogenesis-dependent LTP in the DG without 
affecting the performance of WT mice in CFC or NOR tests (12). 
The lack of behavioral benefits in WT mice upon neurogenesis 
induction could reflect the existence of physiological regulatory 
mechanisms balancing the excess production of newly generated 
cells in WT mice (53). This concept is supported by evidence that 
the number of NeuN+ newborn neurons is not increased upon the 
enhancement of neurogenesis (12). Consistently, in WT mice, lith-
ium neither enhanced the total number of surviving BrdU+ cells 
nor newly generated BrdU+NeuN+ neurons, resulting in a signifi-
cant reduction of their survival rates. Accordingly, apoptotic cells 
were significantly increased after the administration of lithium in 
the DG of WT mice (Supplemental Figure 8), and the number of 
BrdU+NeuN+ newborn neurons was similar in both lithium-treated 
WT and Ts65Dn mice (Figure 6E), supporting the notion that lith-
ium cannot stimulate adult neurogenesis over physiological levels.
Although we acknowledge that lithium might exert diverse 
pleiotropic effects, such as the modulation of brain myo-inositol 
levels (64), our data consistently support the idea that the amelio-
ration of adult neurogenesis underlies lithium effects on behav-
ioral performance in Ts65Dn mice, as revealed by the inability of 
lithium to restore cognitive performance when administered for 
1 week or in combination with the cytostatic drug TMZ. Notably, 
the functional effects (i.e., LTP loss) of neurogenesis knockdown 
appear only when the number of newborn neurons is reduced 
beyond a critical threshold. Indeed, the effects of TMZ on DCX+ 
neuron number are dose dependent. However, only a 25 mg/kg 
dose of TMZ abolishes the LTP of newborn neurons in WT mice. 
This finding is reminiscent of findings in neurodegenerative dis-
orders where clinical symptoms are observed after pathological 
lesions have produced a significant level of damage (65, 66).
The etiology of DS intellectual disability remains poorly under-
stood. Consistent data suggest that Ts65Dn cognitive impair-
ment might arise from an imbalance of excitatory and inhibitory 
neurotransmission (28, 29, 67). It has been shown that the GABA 
antagonists PTX and bilobalide rescue the behavioral deficits of 
Ts65Dn mice when administered for at least 2 consecutive weeks 
(28). Emerging evidence indicates that GABA can also affect 
hippocampal function through neurogenesis (62, 68). Indeed, 
GABAergic inputs to hippocampal progenitor cells reduce NPC 
proliferation, promote activity-dependent neuronal differentia-
tion (68), and regulate the synaptic integration of newly generated 
neurons in the adult hippocampus (62). Within this context, we 
cannot exclude the idea that an imbalance in the excitatory/inhibi-
tory neurotransmission could at least partially contribute to the 
overall impairment of adult neurogenesis in the context of DS. 
However, our data on cultured ADNPCs clearly indicate that cell-
autonomous mechanisms are involved in determining the defec-
tive proliferation of Ts65Dn precursors, suggesting that intrinsic 
neurogenetic pathways might be altered in DS.
The Wnt/β-catenin canonical pathway is a key regulator of NPC 
proliferation and neuronal fate commitment (39) and is activated 
by lithium (38). Consistently, we observed that lithium admin-
istration activates this pathway in the hippocampus of WT and 
Ts65Dn mice. It has been shown that adult hippocampal NPCs 
express receptors and signaling components for Wnt proteins, and 
the Wnt/β-catenin pathway is active in the neurogenic niche of 
adult WT mice (39). Notably, the overexpression of Wnt3 enhances 
neurogenesis, which is almost completely abolished by the inhi-
bition of Wnt signaling in vitro and in vivo (39). Here, we show 
that the reduced proliferation of Ts65Dn ADNPCs is fully restored 
after lithium treatment. This recovery is inhibited upon the expres-
sion of a dominant negative form of TCF4, which is a fundamen-
tal effector that acts downstream of β-catenin (59). Although this 
indicates that Wnt signaling is essential for the lithium-induced 
proliferation of trisomic NPCs, based on the present findings, we 
cannot rule out that other neurogenic pathways might also under-
lie adult neurogenesis impairment in DS. For example, the ago-
nist Sonic Hedgehog (Shh) increases the number of cerebellum 
granule precursor cells when injected into Ts65Dn neonates (33). 
Shh signaling also appears to be active in adult DG stem cells (69). 
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However, the role of this pathway in DS adult neurogenesis 
remains unclear. Moreover, the Notch signaling pathway, which 
is downregulated by DS-associated kinase DIRK1A (70), is also 
crucial for maintaining an essential population of NPCs for DG 
adult neurogenesis (71) and determining cell fate and newborn 
neuron differentiation (72). Further studies are warranted to iden-
tify abnormal neurogenetic pathways in DS and/or their potential 
exploitation for therapies.
In conclusion, our findings strongly indicate that lithium-induced 
adult neurogenesis might have a profound impact on hippocampal 
synaptic plasticity and memory in the Ts65Dn mouse model of 
DS. Studies in DS patients (25, 73, 74) suggest that hippocampal 
dysfunction affects cognitive functions that are typically regulated 
through adult neurogenesis, such as pattern separation (13) and 
cognitive flexibility (11), thus providing a conceptual framework 
for clinical testing of lithium-based therapies in DS. Importantly, 
the effects of lithium manifest at doses achieving serum and brain 
concentrations (Supplemental Figure 2) consistent with the human 
therapeutic range (0.5–1.2 mEq/l) (75). Thus, our data propose that 
lithium-based therapies should be further explored in patients in 
the near future, considering the increased prevalence of DS in the 
European Union (76) and USA (77) over the past decades and the 
increased life expectancy of DS patients consequent to improved 
medical care (78, 79). Conversely, from a long-term perspective, 
our findings implicate adult neurogenesis as a potential target for 
future therapies to treat cognitive disabilities in DS patients.
Methods
Animals and treatment
Female Ts65Dn mice carrying a partial trisomy of chromosome 16 (34) 
were obtained from the Jackson Laboratories and maintained on the origi-
nal genetic background by mating to C57BL/6JEi × C3SnHeSnJ (B6EiC3) 
F1 hybrid males. A veterinarian was employed to control animal health 
and comfort. The mice were housed in filtered cages in a temperature-con-
trolled room with a 12-hour dark/12-hour light cycle and were provided 
access to water and food ad libitum. The animals were genotyped using 
multiplex ligation-dependent probe amplification (MLPA) with a set of 16 
probes previously validated for Ts65Dn trisomic mice (80). WT littermates 
were used as controls throughout the study.
At 5 to 6 months of age, male Ts65Dn and WT littermates (4 to 6 ani-
mals/cage) were randomly assigned to the treatment or control groups. 
The animals in the treatment groups received either standard chow 
(Mucedola) or a diet containing Li2CO3 (2.4 g/kg of chow) for 1 or 4 weeks 
as previously described (37). The serum and brain concentrations of 
lithium were assessed after 1 and 4 weeks of treatment using inductively 
coupled plasma mass spectrometry (ICP-MS). To reduce potential lithium 
toxicity in the kidney, a saline bottle was provided in addition to water to 
all cages (37). The animals in the untreated groups received standard food 
pellets and water and saline bottles.
For the TMZ treatment, doses (12.5 and 25 mg/kg of body weight) previ-
ously shown to inhibit DG neurogenesis without causing detectable side 
effects on weight, motor activity, or inflammation were used (11). TMZ or 
the corresponding vehicle (12.5% DMSO in saline) was i.p. injected into 
mice every other day for 3 weeks, and the subsequent experiments were 
performed 1 week later.
For neuron birth dating, BrdU was administered at 50 mg/kg body 
weight through daily i.p. injections during the fourth week of lithium 
treatment. The mice were sacrificed at 24 hours or 4 weeks after the last 
BrdU injection (81).
Behavioral testing
Various cohorts of mice were used for behavioral testing. Each cohort 
comprised male Ts65Dn mice and WT littermates. The mice were tested 
after 1 week of lithium treatment (acquisition on day 6 and trial on day 7) 
or during the fourth week of lithium treatment. Hippocampal-mediated 
learning and memory was assessed using the OL test, the NOR test, and 
the CFC test. Working memory was tested using the T-maze spontaneous 
alternation test. For the OL and NOR tests, animal behavior was video-
taped throughout all experimental sessions and subsequently analyzed by 
a trained operator blinded to the experimental groups. The motor activity 
was evaluated using a video tracking system (Any-Maze; Ugo Basile) for a 
period of 15 minutes in the same chamber used for the NOR test.
OL test. This test measures spatial memory through an evaluation of 
the ability of mice to recognize the new location of a familiar object with 
respect to spatial cues. Testing was conducted in a black acrylic chamber 
(44 × 44 cm) with white strips on 1 wall of the chamber. The mice were 
first acclimated to the chamber for 15 minutes 1 day prior to testing. The 
mice were exposed to 2 identical objects for 15 minutes during the acquisi-
tion phase and tested at 24 hours later. Object preference was evaluated 
during this session. During the trial session, one of the objects was moved 
to a novel location, and the mice were allowed to explore the objects for 
15 minutes. The objects were cleaned with 70% ethanol after each trial. 
The time spent exploring each object was measured. Exploration was con-
sidered as any investigative behavior (i.e., head orientation, sniffing occur-
ring within < 1.0 cm) or deliberate contact occurring with each object. A 
discrimination index was calculated as the percentage of time spent inves-
tigating the object in the new location minus the percentage of time spent 
investigating the object in the old location: discrimination index = (new 
OL exploration time/total exploration time × 100) – (old OL exploration 
time/total exploration time × 100).
NOR test. The NOR test is based on the natural propensity of rodents 
to preferentially explore novel objects over familiar ones. The experimen-
tal procedure was performed as previously described in DS mouse models 
(28, 49). Testing was conducted in a black acrylic chamber (44 × 44 cm) 
equipped with a digital video recording system. The objects used during the 
task were different in shape, color, size, and material (metal, glass, plastic). 
The mice were acclimated to the chamber for 15 minutes. The following 
day, the mice were placed in the same chamber with 3 different objects for 
a 15-minute acquisition sessions. Object preference was evaluated during 
these sessions. Twenty-four hours later, mice were subjected to a 15-min-
ute testing session, during which they were presented with 2 familiar and 
1 novel object. The objects were counterbalanced between the sessions and 
were cleaned with 70% ethanol after each trial. The time spent exploring 
each object was measured, and the discrimination index was calculated as 
the difference between the percentages of time spent investigating the novel 
object and the time spent investigating the familiar objects: (discrimina-
tion index = (novel object exploration time/total exploration time × 100) – 
(familiar object exploration time/total exploration time × 100).
CFC test. The single-shock CFC test was performed as previously described 
(46). The mice were placed in a fear conditioning system (TSE) consisting of 
a transparent acrylic conditioning chamber (23 × 23 cm) equipped with an 
array of infrared sensors to monitor the animal’s movements and a stain-
less-steel grid floor. The chamber was cleaned with 70% ethanol after each 
trial. The mice were placed in the chamber and after 3 minutes, received an 
electric shock (2 s, 0.75 mA constant electric current) through the floor grid. 
The mice were removed at 15 seconds after the shock. Twenty-four hours 
later, the mice were placed in the same chamber for 3 minutes and, after 
2 hours, were moved to a new context (black chamber with plastic gray floor 
and mint-flavored odor). The freezing behavior was automatically scored 
using the TSE multiconditioning system software.
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supplemented with recombinant FGF-2 and EGF (PeproTech) as previ-
ously described (58). The cells were passaged at 70%–80% confluence using 
Accutase (PAA Laboratories) and replated at 104 cells/cm2.
The cells were transfected through electroporation using an Amaxa 
nucleofector device (Lonza). For the luciferase experiments, the cells were 
transfected with SuperTOPFlash (in which Firefly luciferase expression is 
driven through multiple TCF-binding sites upstream of a minimal TATA 
box; Addgene plasmid 12456) or SuperFOPFlash (in which the TCF-binding 
sites are mutated; Addgene plasmid 12457) plasmids (60), together with the 
pRL-TK vector expressing Renilla luciferase to normalize for transfection 
efficiency. Twenty-four hours after transfection, the ADNPCs were treated 
with LiCl (2 mM) or the corresponding vehicle (2 mM NaCl) or recombinant 
Wnt3a (10 ng/ml; PeproTech), and the luciferase activity was measured at 
24 hours later using a Dual-Luciferase Assay Kit (Promega) according to the 
manufacturer’s instructions. The results were expressed as the ratio of Super-
TOPFlash over SuperFOPFlash normalized luciferase activity.
For the proliferation experiments, the cells were plated on PDL/laminin-
coated coverslips, and 48 hours later, the cells were pulse labeled for 2 hours 
with BrdU (10 μM), fixed, and processed for BrdU immunofluorescence. 
The nuclei were counterstained with DAPI. For each coverslip, the percent-
age of BrdU+ nuclei over the total nuclei was automatically determined 
using ImageJ software (http://rsbweb.nih.gov/ij/) and particles analysis 
plug-in (83). In experiments where the ADNPCs were transfected with 
the EdTC plasmid (61) expressing dominant-negative TCF4 and mCherry 
(Addgene plasmid 24310) or the corresponding control vector expressing 
mCherry alone, the cell proliferation was calculated as the percentage of 
BrdU+Cherry+ double-labeled cells over total Cherry+ cells.
Electrophysiology
Transverse or sagittal hippocampal slices (400 μm) were prepared using 
a Microm HM 650V vibratome, transferred into a holding chamber con-
taining oxygenated artificial cerebrospinal solution (ACSF: 119 mM NaCl, 
2.5 mM KCl, 1.3 mM MgSO4, 1 mM NaH2PO4, 26 mM NaHCO3, 2.5 mM 
CaCl2, and 10 mM glucose, pH 7.4), and incubated for at least 90 minutes 
at room temperature before recording. The slices were transferred into 
a recording chamber and continuously perfused with oxygenated ACSF 
(2 ml/min) at 31°C ± 1°C.
For the DG LTP recording, afferent fibers on the MPP were stimulated 
on the transverse slices using glass capillary electrodes (1–2 MΩ), and the 
field excitatory post-synaptic potentials (fEPSPs) were recorded using 
glass capillary electrodes (4–5 MΩ) filled with ACSF positioned in the 
medial molecular layer of the upper blade. Input/output (I/O) relation-
ships were obtained after 20 minutes of stable recording, and the stimula-
tion intensity that produced 70% of the maximal response was used for 
test pulses and tetanic stimulation. The paired-pulse ratio (PPR) analysis 
of the synaptic connectivity was assessed as previously reported (84). The 
PPR was calculated as the ratio between the fEPSP slopes in response to 
the second and the first stimulus, respectively. As previously reported, the 
paired-pulse stimulation of the MPP resulted in depression of the sec-
ond stimulus (84). Baseline recordings were conducted with a frequency 
of 1 test stimulus every 30 seconds. Only slices showing fEPSPs of 1 mV 
in amplitude or higher were selected for experiments. LTP was induced 
through a tetanic stimulation that consisted of four 100-Hz trains of 
0.5 seconds each repeated every 30 seconds. After induction, the responses 
were recorded every 30 seconds for at least 60 minutes. In some experi-
ments, 100 μM PTX (Sigma-Aldrich) or 1.5 μM Ro25-6981 (Tocris), both 
dissolved in water, were applied at 20 minutes before LTP induction and 
maintained throughout the recording time.
For the CA3-CA1 LTP recording, Schaffer collateral fibers were stimu-
lated on sagittal slices using bipolar tungsten electrodes (0.5 MΩ), and 
T-maze spontaneous alternation. The test was preformed as previously 
described (28). The mice were given a free exploration session, where they 
were briefly confined to the start chamber (for 30 seconds) and permitted 
access to the rest of the maze via the removal of a sliding door in the divid-
er panel for a 7-minute trial. Entry into an arm opposite the previously 
chosen arm was defined as alternation, whereas entry into the previously 
visited arm was not. Thus, the alternation performance was operationally 
defined as the percentage of time the mice alternated (i.e., the number of 
alternations observed/the number of alternation attempts – 1). To control 
for odor cues, the T-maze apparatus was cleaned with 90% ethanol and 
dried after each trial.
Immunohistochemistry and cell quantification
The animals were deeply anesthetized and transcardially perfused 
with 4% paraformaldehyde in 100 mM phosphate buffer, pH 7.4. 
Immunohistochemistry was performed on 30-μm coronal sections as 
previously described (30), with the following primary antibodies: rat 
anti-BrdU (1:200; Abcam); mouse anti-NeuN (1:250; Millipore); mouse 
anti-GFAP (1:500; Sigma-Aldrich); rabbit anti-GFAP (1:100; Abcam); 
rabbit anti-Ki67 (1:200; Thermo Scientific); rabbit anti-Sox2 (1:200; 
Millipore); rabbit anti-DCX (1:1000; Abcam); rabbit anti-CR (1:1000; 
Millipore); and rabbit anti-AC3 (1:750; R&D Systems). Fluorophore-
conjugated (Alexa Fluor 488, Alexa Fluor 568, and Alexa Fluor 647) 
goat secondary antibodies (1:1000; Invitrogen) were used for detec-
tion. For Ki67 immunohistochemistry, antigen retrieval was performed 
with 10 mM citrate buffer, pH 6.0,for 30 minutes at 80°C. For BrdU 
immunohistochemistry, sections were pretreated with 2 N HCl as previ-
ously described (30, 81). The sections were counterstained with the nucle-
ar dye Hoechst-33342 (Sigma-Aldrich).
The stereological cell counting was performed in serial coronal sections 
(180 μm or 240 μm apart) covering the complete rostro-caudal extension 
of the DG as previously described (30, 81). Fluorescence images were cap-
tured with a Nikon A1 confocal scanning microscope. For each section, 
confocal z-stack images (1 μm z-step size) covering the complete DG were 
acquired for DG reconstruction with NIS Element AR software (Nikon). 
Immunolabeled cells in the inner third of the granular cell layer (GCL) 
and the subgranular zone (SGZ, defined as a 10 μm region below the 
GCL) were counted on the reconstructed images by an operator blinded 
to the experimental groups in accordance with the optical dissector prin-
ciple (81). RGL precursors and amplifying precursors were identified by 
the expression of GFAP and Sox2 and distinctive morphological features. 
RGL typically displayed a radial morphology, with the cell body located 
perpendicularly to the GCL and a single thin GFAP-positive process 
spanning the GCL (52). Amplifying progenitors were identified by the 
absence of radial morphology, with the cell body located parallel to the 
GCL. The few mature astrocytes (which were also positive for GFAP and 
Sox2) were excluded on the basis of their stellate morphology. The sur-
vival rates of the BrdU+ cells and their progeny were calculated as the per-
centage of BrdU+ cells observed at 4 weeks with respect to that observed 
at 24 hours after BrdU administration (% survival = [BrdU+ cells at 
4 weeks/BrdU+ cells at 24 hours] × 100) as previously described (82). The 
neuronal cell density in the CA1 and CA3 hippocampal regions was ste-
reologically evaluated on sections stained for NeuN and counterstained 
with Hoechst 33342 as previously described (30).
ADNPCs
NPCs were isolated from the DG of adult (6–8 weeks) WT and Ts65Dn 
mice and cultured as a monolayer on poly-D-lysine (PDL; Sigma-Aldrich) 
and laminin-coated (Roche) flasks in neurobasal medium containing B27, 
GlutaMAX, and penicillin-streptomycin solution (all from Invitrogen) 
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Statistics
The results are presented as the means ± SEM. The statistical analysis was 
performed using SigmaStat (Systat) or Prism (GraphPad) software. Where 
appropriate, the statistical significance was evaluated using a 2-tailed 
unpaired t test and a 1-way or 2-way ANOVA followed by all pairwise Tukey 
or Bonferroni post hoc tests. P < 0.05 was considered significant.
Study approval
A veterinarian was employed to maintain animal health and comfort. The 
mice were housed in filtered cages in a temperature-controlled room with a 
12-hour light/12-hour dark cycle with ad libitum access to water and food. 
All animal experiments were performed in accordance with the guidelines 
established by the European Community Council Directive 2010/63/EU 
of September 22, 2010, and were approved through the Italian Ministry of 
Health and the Italian Institute of Technology (IIT) Ethical Committee.
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the fEPSPs were recorded using glass capillary electrodes (4–5 MΩ) filled 
with ACSF. Both electrodes were positioned in the stratum radiatum. Base-
line recordings were conducted with a frequency of 1 test stimulus every 
30 seconds. A stimulation intensity producing 70% of the maximal 
response was used for test pulses and tetanic stimulation. LTP was induced 
using 2 θ-burst stimulations (TBS: 10 trains of 4 pulses at 100 Hz and 
200 ms apart) repeated after 30 seconds. After induction, the responses 
were recorded every 30 seconds for at least 60 minutes.
The data were 0.1–1000 Hz band-pass filtered and amplified using a 
DAM 80 amplifier (WPI), digitized at a sampling rate of 25 kHz using a 
Digidata 1440A (Molecular Devices) running with Clampex software 
(Molecular Devices). The Clampfit software (Molecular Devices) was 
used for data analysis. The mean slope of fEPSPs recorded during the 
10 minutes preceding LTP induction was considered as 100%. The sta-
tistical significance of LTP induction within each group was determined 
using an unpaired Student’s t test between mean fEPSPs slopes recorded 
0–5 minutes before and 40–45 minutes after LTP induction. The signifi-
cant differences in PPR and I/O relationship for each interstimulus inter-
val and stimulation intensity, respectively, were evaluated using 2-way 
ANOVA for genotype and treatment followed by Tukey’s post hoc test.
Western blotting
Hippocampal tissue was sonicated in lysis buffer (150 mM NaCl, 1 mM 
EGTA, 0.5% Triton X-100, 1% SDS, 10 mM Tris, pH 7.4) containing 1 mM 
PMSF, 10 mM NaF and 1% (v/v) protease and phosphatase inhibitor cock-
tails (Sigma-Aldrich). The samples were clarified through centrifugation at 
20,000 g, and the protein concentration was determined using the BCA kit 
(Pierce). Equal amounts of protein were run on 10% Criterion-XT gels (Bio-
Rad Laboratories) and transferred onto nitrocellulose membranes (GE 
Healthcare). Membranes were probed with mouse anti–active β-catenin 
(clone 8E7; Millipore) (55, 56) and rabbit anti–total β-catenin (Cell Signal-
ing Technologies) antibodies followed by fluorophore-conjugated (anti-
mouse-Cy3 and anti-rabbit-Cy5) goat secondary antibodies (GE Health-
care). The signals were acquired with a Typhoon fluorescent scanner (GE 
Healthcare), and the band intensities were quantified using ImageQuant 
software (GE Healthcare).
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